Should a fourth category be added to the international tumor budding consensus conference tumor budding scoring system in colorectal adenocarcinomas?

Basit Öğe Kaydı
dc.authoridSecinti, Ilke Evrim/0000-0002-8614-3971
dc.authoridOzgur, Tumay/0000-0002-5291-4483
dc.contributor.authorSecinti, Ilke Evrim
dc.contributor.authorOzgur, Tumay
dc.contributor.authorGursoy, Didar
dc.contributor.authorDede, Isa
dc.date.accessioned2024-09-18T20:06:16Z
dc.date.available2024-09-18T20:06:16Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThe aim of this study was to investigate the relationship between tumor budding (TB) and clinicopathologic prognostic criteria in colorectal adenocarcinomas and to discuss the inclusion of the fourth group in the scoring system. A total of 131 cases were included in the study. TB was scored according to the classical 3-tiered scoring system and our proposed 4-tiered scoring system: BD0 (no buds), BD1* (1-4 buds), BD2 (5-9 buds), and BD3 (>= 10 buds). Cytokeratin staining was applied to 80 randomly selected cases and TB scoring was re-evaluated. TB was not observed in 31 (23.7%) of 131 cases and was categorized as BD0. Patients with BD0 budding had lower pT category, AJCC stage, tumor grade, less lymph node metastasis, lymphovascular invasion, tumor deposits (p < 0.05), and longer overall survival than BD1* patients (log-Rank p: 0.018). There was significant compatibility between the evaluation of TB with H&E and cytokeratin (kappa: 0.727, p < 0.001). In conclusion, we think it is valuable to add the BD0 category to the International Tumor Budding Consensus Conference (ITBCC) scores. However, more research with larger cohorts is needed for clinical applicability. H&E staining is sufficient for the assessment of budding, except in conditions such as increased inflammation where the tumor-stroma interface may be obscured.en_US
dc.identifier.doi10.1111/apm.13253
dc.identifier.endpage567en_US
dc.identifier.issn0903-4641
dc.identifier.issn1600-0463
dc.identifier.issue9en_US
dc.identifier.pmid35816469en_US
dc.identifier.scopus2-s2.0-85133670998en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage560en_US
dc.identifier.urihttps://doi.org/10.1111/apm.13253
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8429
dc.identifier.volume130en_US
dc.identifier.wosWOS:000822855200001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofApmisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBuds scoreen_US
dc.subjectcolorectal carcinomaen_US
dc.subjectcytokeratinen_US
dc.subjectscoring systemen_US
dc.subjecttumor buddingen_US
dc.titleShould a fourth category be added to the international tumor budding consensus conference tumor budding scoring system in colorectal adenocarcinomas?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu